ArticleNeuromolecular medicine2025
Fisetin Augments OEC Neuroprotection Through Modulating Neurotrophin/Cytokine Signaling and Activating PI3K/Akt/CREB Pathway in an In Vitro Neurodegenerative Injury.
Article in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The persistence of deleterious substances at lesion sites severely impedes neuronal survival and axonal regeneration following central nervous system (CNS) injury or in neurodegenerative disorders. Therefore, clearing these harmful components and establishing a regeneration-permissive microenvironment are crucial for functional recovery. In this study, primary olfactory ensheathing cells (OECs) isolated from adult SD rats were pharmacologically treated with fisetin, a pharmacological agent. To model CNS injury conditions, neural debris was generated through mechanical disruption of primary neural cells. Neurons exposed to this hostile environment were then treated with conditioned medium from fisetin-activated OECs. Subsequent assessments using qRT-PCR, Western blot, CCK-8 assays, immunofluorescence, and ELISA revealed that fisetin significantly enhanced OEC activation, increasing proliferation and viability. Critically, fisetin-treated OECs markedly mitigated debris-induced neurotoxicity, thereby promoting neuronal survival and neurite outgrowth, which was associated with the upregulated anti-inflammatory cytokines (IL-4, IL-10, TGF-β) and neurotrophic factors (BDNF, GDNF, NGF). Mechanistically, fisetin-activated OECs facilitated neuronal growth via the PI3K/Akt/CREB pathway, suggesting that fisetin potentiates OEC-mediated neuroprotection and neurite regeneration in degenerative environments. These findings may highlight the therapeutic potential of combining OECs therapy with fisetin for CNS injuries and neurodegenerative diseases.
Indexed as
Identifiers
40999096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.